Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Val - thats a fair summary and if im being honest the only real negative from that rns is the revenue which on face is disastrous lets be honest. Although we need to analyse that with some context. They are developing new products which appear to be in demand and the science is good. The R&D department have proven they can deliver. If we dont start seeing growing revenues in the next year or two then i would be concerned. We still have a windfall of cash and potentially more to invest to accelerate this growth. Its hard to see the light but like my investments in the past where i sell on not believeing the future potential they prove me wrong. If i held on to only 2 of them until now i would be retired before 40! One can only hope this turns around and the strategy delivers!
Pi100 what were you expecting? The company is transitioning away from covid it is building a base for growth. Dont expect miracles in a few quarters. This will take time, organically an through M&A. If you dont believe they can then why stay invested?
There is share loss relief but that would be for a qualifying trading company. Nova dont qualify as they dont meet the conditions and also thr shares were purchased and not subscribed for. Therefore the capital loss cannot be offset against general income
Lots going on behind the scenes. Trust the process, revenue generating and cash rich with no debt. In this devasting market investors are looking for companies like this to invest. I am optimistic about the second half of this year lots to look forward to.
https://www.independent.co.uk/news/health/covid-test-rosalind-franklin-laboratory-b2057988.html
When you spend ridiculous amounts on such projects that become redundant to use you need to claw back the money someway!
Captain, what are you not getting? The more the company keep the lid on the dispute details within the piblic domain the less likely a competitor approaches or even attempts a hostile takeover due to the uncertainty. The fact they have now raised a claim for £134m enforced this point further.
Also, they do want to bring in II’s and judging by the comprehensiveness of the presentation i cannot see why some risk averse funds dont take a starter position here at £110 mcap. Potentially, some sharks like BIO may be onnthe prowl aswel. The strengths of this business have always been thr R&D and judging by the development of the covid assays i would bet they develop some really good non-covid ones. Also a key nugget was the M&A could actually increase the timescales for achieving £100m and infact exceed that target.
Overall, think they delivered it well. Hillseekers post sums up really well the position the company finds themselves in currently transtioning from covid to non covid.
The main take away for me is the continuous signalling of utilising the capital for growth using three key areas including M&A. Very significant news given the claim by DHSC. Additionally, James’ response to the dispute question was reassuring saying they see this as progresion essentially. It could be they expected it as dealy tactic but eventually we will get there.
Rns wasnt that bad. The restated revenue guidance has caused the drop but looking beyond that Q4 this year and first halfnnext year could be interesting especially with a favourable dispute resolution. There is vakue in buying at these levels imo and i think funds and Bio will see it that way.
Current year guidance coming in lower than expected in January which is a bit of a bummer but the decline in testing is likely to continue fornthe remainder of the year.
However, more importantly now we have a strategy to innovate and inorganically grow the company to deliver in EXCESS of £100m revenues in 5 years whilst mainting industry standard margins. Industry standard EBITDA sees us at around £35-£40m at a multiple of 20 for the sector values us at £700m. Current MCAP £116m. Value is there to invest. Hopefully some more PDMR’s, maybe BIO increasing and some funds join us.
Lets hear what he has to say at 12 and what the market makes of this!
Wbafc, the last time we had a rns confirming a product was added to the ctda list we actually finished red! The market is not interested in anything covid related any longer. We need a strategy for future growth.